Time for Action: Investing in Health Canada
Recent data reveal a troubling trend: Health Canada is taking longer to assess generic and biosimilar drug submissions, delaying the arrival of cost-saving prescription medications on the market, and increasing costs for Canadian taxpayers and patients.
Both the number and complexity of drug submissions received by Health Canada have been increasing for many years, but resources for its drug review programs have remained largely static and chronically underfunded.
In contrast, regulators in other countries have seen similar submission trends and made the strategic hiring investments needed to meet increased demands and maintain predictable business operations.
The issue is pressing.
As the federal government prepares to unveil its budget on November 4, it is vital that it address these delays through strategic investments in Health Canada’s resources and staffing.
Author's summary: Canada needs to invest in Health Canada to speed up drug approvals.
More News
- "No" to the Mandate for Purchasing Zero-Emission Trucks. IRU Appeals to Brussels for Reason
- Australia’s reduction roadmap calls for a 99 percent cut in new housing emissions
- Huawei showcases grid-forming BESS at 2nd Philippines Future Energy and Grid Summit
- Saudi Arabia's BRKZ lands $30 million debt from Stride Ventures
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- Sweden’s still ahead in the preparedness game — and now it means business
- Benz Hui Dies At 76 from Cancer-Related Organ Failure
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids